KRYS Stock Forecast: Krystal Biotech, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$308
−2.34% on the day

The 12 Wall Street analysts covering Krystal Biotech, Inc. hold a median 12-month price target of $380 — +23.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 83 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$9.4B
Ticker Nerd rank
83/ 100
Median analyst target
$380
Analysts covering
12
Revenue$119.2M+24.1% y/y
Operating income$58.4M
Net income$54.8M
Free cash flow$71.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.0%
1M
−5.2%
YTD
+25.1%
1Y
+51.0%
From 52W high
−18.4%
From 52W low
+51.0%
$204
$378
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Krystal Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
83/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
96
Value
94
Volatility
93
Momentum
86
Revisions
64
Growth
53
Issuance
52
Accruals
42

Quality (96): The business earns solid, repeatable profits on what it owns.

Accruals (42): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KRYS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KRYS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300$350$400$450$500Jan 26Apr 26Jul 26Oct 26KRYSHigh $474Median $380Low $284

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11
Buy
1
Hold
0
Sell
$284
Low
$380
Median
$474
High

The green dot is the last close — the median target sits +23.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
3 Nov 2026CitigroupMaintainsBuy$416 → $412
3 Nov 2026RBC CapitalMaintainsOutperform$400 → $375
3 Nov 2026TD CowenMaintainsBuy$403 → $380
15 Oct 2026HC Wainwright & Co.ReiteratesBuy$361
24 Sept 2026Goldman SachsReinstatesBuy$441
21 Sept 2026B of A SecuritiesMaintainsBuy$392 → $400
14 Aug 2026RBC CapitalInitiatesOutperform$400
4 Aug 2026CitigroupMaintainsBuy$378 → $386
14 July 2026B of A SecuritiesMaintainsBuy$364 → $396
18 June 2026TD CowenMaintainsBuy—
16 June 2026HC Wainwright & Co.MaintainsBuy—
1 June 2026HC Wainwright & Co.ReiteratesBuy—
22 May 2026HC Wainwright & Co.ReiteratesBuy—
18 May 2026HC Wainwright & Co.ReiteratesBuy—
5 May 2026CitigroupMaintainsBuy—
5 May 2026Evercore ISI GroupMaintainsOutperform—
4 May 2026HC Wainwright & Co.ReiteratesBuy—
27 Mar 2026Wolfe ResearchInitiatesPeer Perform—
25 Feb 2026GuggenheimMaintainsBuy—
18 Feb 2026Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KRYS.

Market Radar

This page is one stock. Monday covers all of them.

KRYS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KRYS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Krystal Biotech, Inc. returned +51.0% against +6.9% for the S&P 500, dividends included.

KRYS vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Jan 26Apr 26Jul 26Oct 26KRYSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KRYS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+2.9%
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
43.5×

Cheaper than 19% of US stocks

Price / sales
20.2×

Cheaper than 8% of US stocks

Price / book
6.6×

Cheaper than 12% of US stocks

EV / EBITDA
36.9×

Cheaper than 8% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−20.5%

Higher than 20% of US stocks

Gross margin
94.6%

Higher than 98% of US stocks

Operating margin
48.4%

Higher than 96% of US stocks

Net margin
—
Returns & dividend
Return on equity
17.5%

Higher than 78% of US stocks

Return on assets
10.1%

Higher than 92% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Krystal Biotech, Inc. has a market value of $9.4B and an enterprise value of $8.5B.

  • Revenue in the twelve months to 30 June 2026: $440.5M. The latest quarter grew 24.1% year on year.

  • Net income over the same four quarters: $241.5M, a 54.8% net margin.

  • Diluted earnings per share, trailing twelve months: $7.98.

  • Free cash flow in the twelve months to 30 June 2026: $257.8M.

  • Shares outstanding: 29.6M.

  • Trailing P/E: 43.5×; forward P/E: 34.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Krystal Biotech, Inc. employs 295 people — $1.5M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

KRYS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KRYSKrystal Biotech, Inc.$9.4B83
KYMRKymera Therapeutics, Inc.$9.6B65
PCVXVaxcyte, Inc.$8.7B46
MDGLMadrigal Pharmaceuticals, Inc.$8.7B79
SYRESpyre Therapeutics, Inc.$8.6B33
TGTXTG Therapeutics, Inc.$10.1B78
PRAXPraxis Precision Medicines, Inc.$8.2B34

Take a look at KRYS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Krystal Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about KRYS

What is the KRYS stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Krystal Biotech, Inc. have a median 12-month price target of $380, with estimates ranging from $284 to $474. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KRYS stock a buy right now?

Of the 12 analysts covering Krystal Biotech, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Krystal Biotech, Inc. 83 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KRYS?

As at 21 Nov 2026, Krystal Biotech, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).

Will KRYS stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +23.2% from the last close, and Ticker Nerd's factor model ranks Krystal Biotech, Inc. 83 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KRYS stock forecast for 2030?

No analyst covering Krystal Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRYS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $284 to $474 over the next 12 months.

How has KRYS stock performed over the past year?

Krystal Biotech, Inc. returned +51.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Krystal Biotech, Inc. do?

Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for serious and rare diseases. Its lead product, VYJUVEK, is a redosable gene therapy approved for dystrophic epidermolysis bullosa, a rare inherited skin disorder.

Company

About Krystal Biotech, Inc.

Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for serious and rare diseases. Its lead product, VYJUVEK, is a redosable gene therapy approved for dystrophic epidermolysis bullosa, a rare inherited skin disorder. The company’s work centers on its proprietary HSV-1-based delivery platform, which supports programs across dermatology, respiratory, ophthalmology, oncology, and aesthetics. Through this platform, Krystal Biotech develops therapies designed to address high unmet medical needs and expand treatment options in specialized disease areas. Headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a notable role in the gene therapy market by combining commercial operations with a broader pipeline of investigational genetic medicine candidates.

CEO Mr. Krish S. Krishnan M.B.A., M.S. · 295 employees · United States · https://www.krystalbio.com